jobs

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Exicure, Inc.

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces 1-for-5 Reverse Stock Split
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Reports Second Quarter 2024 Financial Results
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Receives Positive Listing Determination from Nasdaq
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Reports First Quarter 2024 Financial Results
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Reports Full Year 2023 Financial Results
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Received Nasdaq Notice of a Delisting Determination
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Reports Third Quarter 2023 Financial Results
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News Instagram Instagram
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

922 Allowance Ave SE
Medicine Hat, AB T1A 3G7

Office hours: 8:30 a.m.-4:30 p.m. Monday to Friday, closed Saturday Sunday and statutory holidays.

[P] 403.527.1101
[F] 403-527-0737

Print Advertising: 403.528.5659
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2024 The Medicine Hat News